Literature DB >> 43870

Pharmacokinetics of nadolol, a beta-receptor antagonist: administration of therapeutic single- and multiple-dosage regimens to hypertensive patients.

J Dreyfuss, D L Griffith, S M Singhvi, J M Shaw, J J Ross, R A Vukovich, D A Willard.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 43870     DOI: 10.1002/j.1552-4604.1979.tb01641.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


× No keyword cloud information.
  14 in total

1.  Comparison of single-dose and steady-state nadolol plasma concentrations.

Authors:  J J Krukemyer; H Boudoulas; P F Binkley; J J Lima
Journal:  Pharm Res       Date:  1990-09       Impact factor: 4.200

2.  A dose-ranging study to evaluate the beta 1-adrenoceptor selectivity of bisoprolol.

Authors:  B J Lipworth; N A Irvine; D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  The effects of chronic dosing on the beta 1 and beta 2-adrenoceptor antagonism of betaxolol and atenolol.

Authors:  B J Lipworth; N A Irvine; D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

4.  Bioequivalence of a highly variable drug: an experience with nadolol.

Authors:  R G Buice; V S Subramanian; K L Duchin; S Uko-Nne
Journal:  Pharm Res       Date:  1996-07       Impact factor: 4.200

5.  Pharmacokinetics of nadolol in healthy subjects.

Authors:  M Schäfer-Korting; N Bach; H Knauf; E Mutschler
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

6.  Nadolol in thyrotoxicosis.

Authors:  N R Peden; T E Isles; I H Stevenson; J Crooks
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

7.  Comparison between atenolol and nadolol in essential hypertension at rest and on exercise.

Authors:  R G Wilcox; J R Hampton
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

8.  Nadolol in human serum and breast milk.

Authors:  R G Devlin; K L Duchin; P M Fleiss
Journal:  Br J Clin Pharmacol       Date:  1981-09       Impact factor: 4.335

9.  Celiprolol double-peak occurrence and gastric motility: nonlinear mixed effects modeling of bioavailability data obtained in dogs.

Authors:  E Lipka; I D Lee; P Langguth; H Spahn-Langguth; E Mutschler; G L Amidon
Journal:  J Pharmacokinet Biopharm       Date:  1995-06

10.  Nadolol in combination with indapamide and xipamide in resistant hypertensives.

Authors:  S Dean; M J Kendall; S Potter; M H Thompson; D A Jackson
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.